Key Highlights
- The nine-month net loss shrank to roughly USD 6.8 million for 2026 from USD 24.4 million a year earlier, with non-cash items declining to USD 3.0 million from USD 18.7 million.
- Revenue over the nine months grew about 22%, reaching nearly USD 6.4 million against USD 5.3 million, and third-quarter sales rose 26% to roughly USD 2.2 million as new clinics came on board.
- On September 30, 2026, cash amounted to about USD 3.7 million, while Equity rose to USD 18.0 million from USD 7.2 million on December 31, 2025.
- Going concern language remains in the filing because the company depends on Debt and equity raises, and its accumulated Deficit reached USD 98.2 million.
Purchased Clinics Boost Top-Line Growth
The quarterly statement, filed November 16, 2026, covers the nine months ended September 30. INVO Fertility (NASDAQ:IVF) runs fertility clinics and sells its INVOcell device for assisted reproduction. Of the USD 1.2 million nine-month Revenue increase, about USD 0.7 million traced to purchased facilities: the Indiana Clinic, acquired in February, and the Alabama Clinic, now wholly owned since late June. Organic expansion at clinics already operating supplied the remaining USD 0.5 million, and acceptance into the Progyny network during the first quarter contributed as well. Consideration for Indiana totalled USD 760,000, made up of USD 360,000 in cash and USD 400,000 in Series D preferred shares, while the other half of Alabama cost USD 175,001. Services costs climbed roughly 26% to USD 4.1 million.
Lower Non-Cash Charges Drive the Better Result
Most of the gain for INVO Fertility (NASDAQ:IVF) comes from non-cash items that were heavy in 2025. A third-quarter debt extinguishment charge of USD 1.4 million, linked to an amended debenture, was absent this year. Third-quarter SG&A held around USD 2.1 million, and share-based pay dropped from USD 0.5 million to USD 0.1 million. Derivative Fair Value changes tied to the Any Market Purchase Agreement produced a USD 0.6 million loss this quarter. Interest and financing charges declined to USD 0.2 million from USD 0.3 million. Liabilities shrank by USD 5.5 million since December 31, 2025, while Assets grew USD 5.3 million, lifting equity.
Equity Raises, Financing Gaps and the Nasdaq Matter
January 2026 Warrant exercises brought in around USD 7.1 million, and an August draw under the Any Market Purchase Agreement added USD 3.5 million. Of that money, USD 2.2 million and USD 1.3 million went toward deferred payments for WFI acquisitions. Nine-month operating cash burn dropped to USD 4.7 million from USD 7.0 million. A 1-for-5 reverse split became effective March 27, 2026, leaving 1,192,860 shares on November 16. Nasdaq resolved its late-filing concern on June 23, 2026, after the Annual Report arrived June 2 and the first-quarter filing followed on June 22. Management intends to grow organically and acquire additional profitable clinics.
Where Things Stand
Only partly. INVO Fertility (NASDAQ:IVF) lost less mainly because lower non-cash expenses from 2025 did not return, with clinic sales lending a hand. The Business still burns cash, using USD 4.7 million over nine months while holding USD 3.7 million. Watch next for more clinic deals, extra funding under the purchase agreement and any move to lift the Going Concern wording.






Please wait processing your request...